drugset / Trial / NCT06202378
Safety and Efficacy of SHPL-49 Injection in Participants With Acute Ischemic Stroke
Phase 2
Completed
270 enrolled
Shanghai Hutchison Pharmaceuticals Limited
Beijing Tiantan Hospital · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is designed to determine the safety and efficacy of SHPL-49 intravenous infusion for 7 consecutive days in the treatment of acute ischemic stroke subjects.
Timeline
- Start
- 2023-12-29
- Primary completion
- 2024-11-26
- Completion
- 2024-12-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHPL-49 | Unknown | 3 unknown | Intravenous |
| Subject | SHPL-49 | Unknown | 6 unknown | Intravenous |